| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College School of Medicine, London, United Kingdom; and
Division of Biochemistry and Molecular Biology, University of Glasgow, Glasgow, United Kingdom.
IL-5 is implicated in the pathogenesis of asthma and is predominantly released from T lymphocytes of the Th2 phenotype. In anti-CD3 plus anti-CD28-stimulated PBMC, albuterol, isoproterenol, rolipram, PGE2, forskolin, cholera toxin, and the cAMP analog, 8-bromoadenosine cAMP (8-Br-cAMP) all inhibited the release of IL-5 and lymphocyte proliferation. Although all of the above compounds share the ability to increase intracellular cAMP levels and activate protein kinase (PK) A, the PKA inhibitor H-89 failed to ablate the inhibition of IL-5 production mediated by 8-Br-cAMP, rolipram, forskolin, or PGE2. Similarly, H-89 had no effect on the cAMP-mediated inhibition of lymphocyte proliferation. Significantly, these observations occurred at a concentration of H-89 (3 µM) that inhibited both PKA activity and CREB phosphorylation in intact cells. Additional studies showed that the PKA inhibitors H-8, 8-(4-chlorophenylthio) adenosine-3',5'-cyclic monophosphorothioate Rp isomer, and a myristolated PKA inhibitor peptide also failed to block the 8-Br-cAMP-mediated inhibition of IL-5 release from PBMC. Likewise, a role for PKG was considered unlikely because both activators and inhibitors of this enzyme had no effect on IL-5 release. Western blotting identified Rap1, a downstream target of the cAMP-binding proteins, exchange protein directly activated by cAMP/cAMP-guanine nucleotide exchange factors 1 and 2, in PBMC. However, Rap1 activation assays revealed that this pathway is also unlikely to be involved in the cAMP-mediated inhibition of IL-5. Taken together, these results indicate that cAMP-elevating agents inhibit IL-5 release from PBMC by a novel cAMP-dependent mechanism that does not involve the activation of PKA.
This article has been cited by other articles:
|
|
 |
|
  N. Yano, D. Suzuki, M. Endoh, T. C. Zhao, J. F. Padbury, and Y.-T. Tseng A Novel Phosphoinositide 3-Kinase-dependent Pathway for Angiotensin II/AT-1 Receptor-mediated Induction of Collagen Synthesis in MES-13 Mesangial Cells J. Biol. Chem., June 29, 2007; 282(26): 18819 - 18830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Raskovalova, A. Lokshin, X. Huang, Y. Su, M. Mandic, H. M. Zarour, E. K. Jackson, and E. Gorelik Inhibition of Cytokine Production and Cytotoxic Activity of Human Antimelanoma Specific CD8+ and CD4+ T Lymphocytes by Adenosine-Protein Kinase A Type I Signaling Cancer Res., June 15, 2007; 67(12): 5949 - 5956. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Zhou, T. S. Blackwell, K. Goleniewska, J. F. O'Neal, G. A. FitzGerald, M. Lucitt, R. M. Breyer, and R. S. Peebles Jr. Prostaglandin I2 analogs inhibit Th1 and Th2 effector cytokine production by CD4 T cells J. Leukoc. Biol., March 1, 2007; 81(3): 809 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Colmone, S. Li, and C.-R. Wang Activating Transcription Factor/cAMP Response Element Binding Protein Family Member Regulated Transcription of CD1A J. Immunol., November 15, 2006; 177(10): 7024 - 7032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Robinson-White, W. W. Leitner, E. Aleem, P. Kaldis, I. Bossis, and C. A. Stratakis PRKAR1A Inactivation Leads to Increased Proliferation and Decreased Apoptosis in Human B Lymphocytes Cancer Res., November 1, 2006; 66(21): 10603 - 10612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Lokshin, T. Raskovalova, X. Huang, L. C. Zacharia, E. K. Jackson, and E. Gorelik Adenosine-mediated inhibition of the cytotoxic activity and cytokine production by activated natural killer cells. Cancer Res., August 1, 2006; 66(15): 7758 - 7765. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Giembycz and R. Newton Beyond the dogma: novel {beta}2-adrenoceptor signalling in the airways. Eur. Respir. J., June 1, 2006; 27(6): 1286 - 1306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Feng, E. M. Beller, S. Bagga, and J. A. Boyce Human mast cells express multiple EP receptors for prostaglandin E2 that differentially modulate activation responses Blood, April 15, 2006; 107(8): 3243 - 3250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gambaryan, E. Butt, P. Tas, A. Smolenski, B. Allolio, and U. Walter Regulation of aldosterone production from zona glomerulosa cells by ANG II and cAMP: evidence for PKA-independent activation of CaMK by cAMP Am J Physiol Endocrinol Metab, March 1, 2006; 290(3): E423 - E433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Giembycz Phosphodiesterase-4: Selective and Dual-Specificity Inhibitors for the Therapy of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, November 1, 2005; 2(4): 326 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Oostendorp, D. S. Postma, H. Volders, H. Jongepier, H. F. Kauffman, H. M. Boezen, D. A. Meyers, E. R. Bleecker, S. A. Nelemans, J. Zaagsma, et al. Differential Desensitization of Homozygous Haplotypes of the {beta}2-Adrenergic Receptor in Lymphocytes Am. J. Respir. Crit. Care Med., August 1, 2005; 172(3): 322 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Smith, F. Wang, K. N. Wilkinson, K. J. Savage, U. Klein, D. S. Neuberg, G. Bollag, M. A. Shipp, and R. C. T. Aguiar The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma Blood, January 1, 2005; 105(1): 308 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Feng, A. G. Mery, E. M. Beller, C. Favot, and J. A. Boyce Adenine Nucleotides Inhibit Cytokine Generation by Human Mast Cells through a Gs-Coupled Receptor J. Immunol., December 15, 2004; 173(12): 7539 - 7547. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Smith, L. B. Cieslinski, R. Newton, L. E. Donnelly, P. S. Fenwick, A. G. Nicholson, P. J. Barnes, M. S. Barnette, and M. A. Giembycz Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a Selective Inhibitor of Phosphodiesterase 7: In Vitro Studies in Human Monocytes, Lung Macrophages, and CD8+ T-Lymphocytes Mol. Pharmacol., December 1, 2004; 66(6): 1679 - 1689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Meja, M. C. Catley, L. M. Cambridge, P. J. Barnes, H. Lum, R. Newton, and M. A. Giembycz Adenovirus-Mediated Delivery and Expression of a cAMP-Dependent Protein Kinase Inhibitor Gene to BEAS-2B Epithelial Cells Abolishes the Anti-Inflammatory Effects of Rolipram, Salbutamol, and Prostaglandin E2: A Comparison with H-89 J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 833 - 844. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Robinson-White, T. R. Hundley, M. Shiferaw, J. Bertherat, F. Sandrini, and C. A. Stratakis Protein kinase-A activity in PRKAR1A-mutant cells, and regulation of mitogen-activated protein kinases ERK1/2 Hum. Mol. Genet., July 1, 2003; 12(13): 1475 - 1484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Martin, I. Dransfield, C. Haslett, and A. G. Rossi Cyclic AMP Regulation of Neutrophil Apoptosis Occurs via a Novel Protein Kinase A-independent Signaling Pathway J. Biol. Chem., November 21, 2001; 276(48): 45041 - 45050. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
